Production Capacity Emerges as a Differentiator Amid Surging GLP-1 Demand
Demand for glucagon-like peptide-1 (GLP-1) obesity drugs is outpacing supply, and the profit structure of active pharmaceutical ingredient (API) makers and contract manufacturers (CDMOs) is being redrawn. Capex and contract backlogs are becoming the new map of revenue distribution across the entire production network.
Different Profit Profiles: API Makers vs. CDMOs
Lilly is the biggest beneficiary in the global obesity drug market. At $1,417.99 (November 4, 2026 close), LLY has posted a 19.14% cumulative return over three months. Revenue is up 38.6% year-over-year in the same period, with a net margin of 31.9%—showing the high margins available to API-focused operations.
Thermo Fisher plays a different role: provider of manufacturing infrastructure and services. Its November 4 close was $706.16, with a 21.84% three-month return. But sales growth was only 9.1%, well below Lilly’s 38.6%, and net margin came to just 14.9%. High capital intensity and thin margins typify the CDMO service business.
Why Securing Production Capacity Matters Now: Four Factors
1. Supply Constraints Determine Pricing Power: GLP-1 drugs come in different forms—injectable and oral—each with different manufacturing complexity. Injectables have low throughput per hour and heavy capex in aseptic fill-and-finish. When a CDMO like Thermo Fisher hits capacity limits, it raises costs. Lilly can immediately pass higher outsourced production costs to customers through price hikes.
2. P/E Gap Signals Market Expectations: LLY’s P/E is 45.1, while TMO’s is 36.0. Lilly’s premium multiple reflects expectations of sustained earnings growth, while Thermo Fisher’s lower multiple reflects the market’s view of heavy capex burdens and margin constraints in CDMO expansion.
3. Utilization Shifts From Idle to Tight: CDMOs spent three years sitting on excess capacity. Now in 2026, GLP-1 demand is filling idle lines. Once existing capacity maxes out, new capex decisions (cold storage, automation lines) are underway. During this expansion, integrated CDMOs like Thermo Fisher capture additional revenue not just from their own lines but from engineering consulting and capex recommendations to customers.
4. Oral Formulations Remain a Bottleneck: Oral GLP-1 drugs are harder to manufacture than injectables and remain in capacity expansion. LLY’s expanding oral portfolio locks in long-term CDMO contracts to secure supply, which creates advance payment flows for CDMOs and improves cash position.
Why LLY and TMO Despite Different Profiles: Structural Strengths and Weaknesses
Lilly’s Strength: High patent and regulatory barriers protect API profits, and outsourcing capex preserves capital efficiency. A 31.9% margin shows how cost inflation is passed through via price increases.
Lilly’s Weakness: Supply-chain risk is spread across multiple CDMOs; rising dependence on single facilities exposes it to geopolitical factors (export controls, factory shutdowns).
Thermo Fisher’s Strength: GLP-1 demand surge has cleared excess capacity and accumulated contracts, giving it negotiating power to secure higher-priced contracts than with legacy customers.
Thermo Fisher’s Weakness: Capital-intensive operations demand heavy capex for expansion, and dependence on single-customer contracts risks idle capacity if one customer’s agreement ends. A 14.9% net margin reflects structural CDMO margin limits.
In Summary
In this rapid GLP-1 growth phase, LLY preserves high API margins while outsourcing capex to protect capital efficiency. TMO faces margin constraints but has gained long-term contract stickiness and pricing upside. This revenue split may be redrawn as the industry matures.
This article is for information only and is not investment advice.